BACKGROUND/AIMS: We had previously reported that acute kidney injury (AKI) in warfarin-treated chronic kidney disease (CKD) patients may occur shortly after an acute increase in the International Normalization Ratio (INR) >3.0 with formation of occlusive red blood casts. Recovery from this warfarin-associated AKI is poor. Here we investigated whether excessive warfarin therapy could accelerate the progression of CKD. METHODS: We analyzed serum creatinine (SC) and INR in 103 consecutive CKD patients on warfarin therapy in our Nephrology program from 2005 to the present. RESULTS: Forty-nine patients experienced at least 1 episode of INR >3.0. Of these, 18 patients (37%, Group 1) developed an unexplained increase in SC > or =0.3 mg/dl coincident with INR >3.0 (mean SC increase 0.61 +/- 0.44 mg/dl); 31 patients (63%, Group 2) showed stable SC (mean SC change 0.04 +/- 0.19 mg/dl). Subsequent CKD progression was accelerated in Group 1, but not in Group 2. The 2 groups were not different with respect to demographics, comorbidities, blood pressure, or therapies. However, African Americans were overrepresented in Group 1 (p = 0.035). CONCLUSIONS: Overanticoagulation is associated with faster progression of CKD in a high percentage of patients. Our results indicate the need for prospective trials. Nevertheless, we suggest that our findings are sufficiently compelling at this point to justify extra caution in warfarin-treated CKD patients to avoid overanticoagulation. Copyright 2010 S. Karger AG, Basel.
BACKGROUND/AIMS: We had previously reported that acute kidney injury (AKI) in warfarin-treated chronic kidney disease (CKD) patients may occur shortly after an acute increase in the International Normalization Ratio (INR) >3.0 with formation of occlusive red blood casts. Recovery from this warfarin-associated AKI is poor. Here we investigated whether excessive warfarin therapy could accelerate the progression of CKD. METHODS: We analyzed serum creatinine (SC) and INR in 103 consecutive CKDpatients on warfarin therapy in our Nephrology program from 2005 to the present. RESULTS: Forty-nine patients experienced at least 1 episode of INR >3.0. Of these, 18 patients (37%, Group 1) developed an unexplained increase in SC > or =0.3 mg/dl coincident with INR >3.0 (mean SC increase 0.61 +/- 0.44 mg/dl); 31 patients (63%, Group 2) showed stable SC (mean SC change 0.04 +/- 0.19 mg/dl). Subsequent CKD progression was accelerated in Group 1, but not in Group 2. The 2 groups were not different with respect to demographics, comorbidities, blood pressure, or therapies. However, African Americans were overrepresented in Group 1 (p = 0.035). CONCLUSIONS: Overanticoagulation is associated with faster progression of CKD in a high percentage of patients. Our results indicate the need for prospective trials. Nevertheless, we suggest that our findings are sufficiently compelling at this point to justify extra caution in warfarin-treated CKDpatients to avoid overanticoagulation. Copyright 2010 S. Karger AG, Basel.
Authors: Sergey V Brodsky; Anjali Satoskar; Jun Chen; Gyongyi Nadasdy; Jeremiah W Eagen; Mirza Hamirani; Lee Hebert; Edward Calomeni; Tibor Nadasdy Journal: Am J Kidney Dis Date: 2009-07-04 Impact factor: 8.860
Authors: Nita A Limdi; T Mark Beasley; Melissa F Baird; Joyce A Goldstein; Gerald McGwin; Donna K Arnett; Ronald T Acton; Michael Allon Journal: J Am Soc Nephrol Date: 2009-02-18 Impact factor: 10.121
Authors: Kyle Ware; Polina Brodsky; Anjali A Satoskar; Tibor Nadasdy; Gyongyi Nadasdy; Haifeng Wu; Brad H Rovin; Udayan Bhatt; Jon Von Visger; Lee A Hebert; Sergey V Brodsky Journal: J Am Soc Nephrol Date: 2011-09-01 Impact factor: 10.121
Authors: Douglas L Feinstein; Belinda S Akpa; Manuela A Ayee; Anne I Boullerne; David Braun; Sergey V Brodsky; David Gidalevitz; Zane Hauck; Sergey Kalinin; Kathy Kowal; Ivan Kuzmenko; Kinga Lis; Natalia Marangoni; Michael W Martynowycz; Israel Rubinstein; Richard van Breemen; Kyle Ware; Guy Weinberg Journal: Ann N Y Acad Sci Date: 2016-05-31 Impact factor: 5.691
Authors: A Ozcan; K Ware; E Calomeni; T Nadasdy; R Forbes; A A Satoskar; G Nadasdy; B H Rovin; L A Hebert; S V Brodsky Journal: Am J Nephrol Date: 2012-04-02 Impact factor: 3.754